Amylyx Pharmaceuticals (NASDAQ:AMLX) Announces Quarterly Earnings Results, Misses Estimates By $0.70 EPS

Amylyx Pharmaceuticals (NASDAQ:AMLXGet Free Report) released its quarterly earnings data on Friday. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of $0.24 by ($0.70), Zacks reports. Amylyx Pharmaceuticals had a positive return on equity of 3.92% and a negative net margin of 17.86%. The firm had revenue of $88.64 million for the quarter, compared to analysts’ expectations of $113.26 million. During the same quarter in the previous year, the business earned $0.02 earnings per share.

Amylyx Pharmaceuticals Stock Down 7.1 %

NASDAQ:AMLX opened at $1.76 on Monday. The stock has a market capitalization of $119.36 million, a price-to-earnings ratio of -1.64 and a beta of -0.68. Amylyx Pharmaceuticals has a 52 week low of $1.70 and a 52 week high of $30.50. The firm has a 50 day moving average of $3.77 and a 200 day moving average of $11.23.

Analysts Set New Price Targets

Several brokerages have recently commented on AMLX. Leerink Partnrs lowered Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, March 11th. Mizuho lowered shares of Amylyx Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, March 18th. Robert W. Baird downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Monday, March 11th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Amylyx Pharmaceuticals in a report on Friday. Finally, The Goldman Sachs Group reissued a “neutral” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $32.67.

Get Our Latest Analysis on AMLX

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 4,135 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total value of $77,448.55. Following the completion of the sale, the chief executive officer now directly owns 3,023,002 shares in the company, valued at $56,620,827.46. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 2,838 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $18.76, for a total value of $53,240.88. Following the sale, the insider now directly owns 46,245 shares of the company’s stock, valued at $867,556.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Joshua B. Cohen sold 4,135 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total value of $77,448.55. Following the completion of the sale, the chief executive officer now owns 3,023,002 shares in the company, valued at approximately $56,620,827.46. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,305 shares of company stock valued at $193,098. 11.70% of the stock is currently owned by insiders.

About Amylyx Pharmaceuticals

(Get Free Report)

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

Further Reading

Earnings History for Amylyx Pharmaceuticals (NASDAQ:AMLX)

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.